title: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months.
abstract: BACKGROUND
  On-demand therapy may offer an effective approach to the long-term management of gastro-oesophageal reflux disease (GORD) without oesophagitis.
  
  
  OBJECTIVE
  To examine the efficacy of the novel proton pump inhibitor esomeprazole as on-demand therapy in endoscopy-negative GORD.
  
  
  METHODS
  Endoscopy-negative GORD patients who achieved complete resolution of heartburn after short-term esomeprazole or omeprazole treatment (n = 721) were randomized to esomeprazole 20 mg (n = 282), 40 mg (n = 293) or placebo (n = 146) on demand (maximum one dose/day) for 6 months. The primary and secondary efficacy endpoints were time to study discontinuation due to (i) unwillingness to continue and (ii) inadequate control of heartburn, respectively.
  
  
  RESULTS
  Both doses of esomeprazole were more effective than placebo. During the 6-month period, 42% of placebo recipients discontinued treatment due to unwillingness to continue, compared with 8% and 11% of esomeprazole 20 mg and 40 mg recipients, respectively. Overall, more patients treated with esomeprazole were free from gastrointestinal symptoms after 6 months of on-demand therapy.
  
  
  CONCLUSIONS
  Esomeprazole 20 mg was superior to placebo for on-demand treatment of GORD; a higher dose did not confer additional clinical benefit. Over 90% of patients were willing to continue on-demand treatment with esomeprazole 20 mg over a 6-month period.
authors.affiliation: Department of Medicine, University of Sydney, Clinical Science Building, Nepean Hospital, Penrith, Australia. ntalley@blackburn.med.su.oz.au
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Talley
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Venables
authors.forename: Jonathan R B
authors.initials: JR
authors.lastname: Green
authors.forename: David
authors.initials: D
authors.lastname: Armstrong
authors.forename: Kevin P J
authors.initials: KP
authors.lastname: O'Kane
authors.forename: Mustafa
authors.initials: M
authors.lastname: Giaffer
authors.forename: Karna D
authors.initials: KD
authors.lastname: Bardhan
authors.forename: Rolf G S
authors.initials: RG
authors.lastname: Carlsson
authors.forename: Samuel
authors.initials: S
authors.lastname: Chen
authors.forename: Göran S
authors.initials: GS
authors.lastname: Hasselgren
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D064098:Esomeprazole; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000188:drug therapy*; D005773:Gastroscopy; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D017060:Patient Satisfaction; D011336:Probability; D012016:Reference Values; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D009853:Omeprazole; D064098:Esomeprazole